-
2025-521627-78-00
5
2026-01-28
Neoplasms, Lung
-
2025-522400-24-00
10
2026-01-27
Metastatic urothelial cancer
-
2024-517397-25-00
1
2026-01-26
B-cell Mediated Autoimmune Diseases
-
2024-514435-20-00
5
2025-12-23
Phenylketonuria
-
2025-522860-34-00
5
2025-12-16
Chronic lymphocytic leukemia (CLL)
-
2024-513586-39-00
5
2025-12-10
Prostate Cancer
-
2025-521382-27-00
10
2025-12-04
Moderately to Severely Active Crohn's Disease
-
2025-521381-10-00
5
2025-12-03
Moderately to Severely Active Ulcerative Colitis
-
2024-512577-27-00
5
2025-12-02
Chronic kidney disease in paediatric patients
-
2025-521737-91-00
4
2025-11-25
Neoplasm malignant with KRAS G12C mutation
-
2024-516602-28-00
7
2025-11-21
Advanced Solid Tumors
-
2023-503447-33-00
4
2025-11-13
febrile Urinary Tract Infection (fUTI)
-
2025-520639-17-00
4
2025-11-12
High-risk localized or locally advanced prostate adenocarcinoma
-
2024-520190-12-00
5
2025-11-10
Breast Cancer: triple negative breast cancer (TNBC) and hormone recept
-
2024-517131-52-00
5
2025-11-03
Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lym
-
2024-519917-72-00
5
2025-10-29
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
-
2025-520490-38-00
3
2025-10-13
Haemophilia A with or without inhibitors. Proposed indication under de
-
2024-516652-18-00
5
2025-10-10
Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
-
2025-520672-26-00
9
2025-09-16
Gastrointestinal Neoplasms
-
2024-519814-29-00
4
2025-09-12
Advanced or Metastatic Non-small Cell Lung Cancer
-
2024-516982-35-00
5
2025-09-11
Ovarian Cancer
-
2023-506135-14-00
11
2025-09-10
Breast cancer
-
2024-516822-67-00
10
2025-08-14
Hypochondroplasia
-
2023-509630-19-00
5
2025-07-31
Esophageal Squamous Cell Carcinoma (ESCC)